The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 32, No. 9, pp. 947-961. DOI 10.1345/aph.17298
© 1998 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lewis, D.
Right arrow Articles by Berg, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lewis, D.
Right arrow Articles by Berg, M.

Research Articles

Drug and environmental factors associated with adverse pregnancy outcomes. Part II: Improvement with folic acid

DP Lewis, DC Van Dyke, PJ Stumbo, and MJ Berg

OBJECTIVE: To provide a comprehensive review of periconceptional folic acid supplementation and factors affecting folate supplementation trials. DATA SOURCES: A MEDLINE search was conducted through December 1997. Additional sources were obtained from Current Contents and citations from the references obtained. Search terms included folate, folic acid, neural tube defect, spina bifida, and anencephaly. STUDY SELECTION: Relevant animal and human studies examining the effects of folate were reviewed. DATA EXTRACTION: Data collected included: type of study, folate dosing, dietary folate intake, serum and red blood cell folate concentrations, type of defect(s) studied, vitamin usage, parental risk factors, factors affecting trial results. DATA SYNTHESIS: Nine key factors have been identified that affect outcomes of folic acid supplementation trials. Daily doses of 0.8 mg decreased the occurrence and doses of 4 mg decreased the recurrence of neural tube defects in randomized clinical trials. Since lower folic acid doses were effective in nonrandomized trials, research is needed to determine the lowest effective dosage. Other benefits involving pregnancy outcome are suggested. CONCLUSIONS: Women of childbearing age should take a daily folic acid supplement to reduce the risk of pregnancies resulting in infants with a neural tube defect and other potential adverse pregnancy outcomes. Further health benefits from folic acid supplementation are reviewed in Part III of this series.


This article has been cited by other articles:


Home page
 JBJSHome page
K. Kusumi and P. D. Turnpenny
Formation Errors of the Vertebral Column
J. Bone Joint Surg. Am., February 1, 2007; 89(suppl_1): 64 - 71.
[Full Text] [PDF]

Home page
 Clin Med ResHome page
P. F. Giampietro, R. D. Blank, C. L. Raggio, S. Merchant, F. S. Jacobsen, T. Faciszewski, S. K. Shukla, A. R. Greenlee, C. Reynolds, and D. B. Schowalter
Congenital and Idiopathic Scoliosis: Clinical and Genetic Aspects
Clin. Med. Res., April 1, 2003; 1(2): 125 - 136.
[Abstract] [Full Text] [PDF]

Home page
 Am J EpidemiolHome page
S. Hernandez-Diaz, M. M. Werler, A. M. Walker, and A. A. Mitchell
Neural Tube Defects in Relation to Use of Folic Acid Antagonists during Pregnancy
Am. J. Epidemiol., May 15, 2001; 153(10): 961 - 968.
[Abstract] [Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 1998 by Harvey Whitney Books Company.